{"id":389021,"date":"2024-12-10T00:00:00","date_gmt":"2024-12-10T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfon0006-2024-biopharma-non-hodgkins-lymphoma-and-chronic-lymphocytic-leukemia-disease-landscape-forecast-g7-2024\/"},"modified":"2026-03-31T10:27:46","modified_gmt":"2026-03-31T10:27:46","slug":"dlsfon0006-2024-biopharma-non-hodgkins-lymphoma-and-chronic-lymphocytic-leukemia-disease-landscape-forecast-g7-2024","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfon0006-2024-biopharma-non-hodgkins-lymphoma-and-chronic-lymphocytic-leukemia-disease-landscape-forecast-g7-2024\/","title":{"rendered":"Non-Hodgkin&#8217;s Lymphoma and Chronic Lymphocytic Leukemia | Disease Landscape &#038; Forecast | G7 | 2024"},"content":{"rendered":"<p>The multibillion dollar non-Hodgkin\u2019s lymphoma (NHL) \/ chronic lymphocytic leukemia (CLL) therapy market is dynamic and experiencing substantial growth. The covalent BTK inhibitors ibrutinib (Imbruvica, J&#038;J Innovative Medicine), acalabrutinib (Calquence, AstraZeneca), and zanubrutinib (Brukinsa, BeiGene) are transforming the treatment of NHL\u00a0\/\u00a0CLL, and we expect the noncovalent BTK inhibitor pirtobrutinib (Jaypirca, Eli Lilly) to carve out a niche for the treatment of patients who relapse or are refractory to covalent BTK inhibitor therapy. BCL-2 inhibitors, CD20-directed antibodies, and CAR T-cell therapies are also key contributors to NHL \/ CLL therapy sales. Continued uptake of these agents, and label expansions transitioning their use to earlier lines of treatment will fuel sales over the 2023-2033 forecast period, and contribute to a shift away from conventional immunochemotherapy regimens. BiTEs are the latest class of agent to launch in NHL \/ CLL, and agents including mosunetuzumab (Lunsumio, Roche), epcoritamab (Epkinly \/ Tepkinly, Genmab \/ AbbVie), and glofitamab (Columvi, Roche) will garner substantial uptake and drive market growth over the forecast period.<\/p>\n<p><strong>Questions answered<\/strong><\/p>\n<ul>\n<li>What is the size of the clinically and commercially relevant drug-treatable NHL \/ CLL populations, and how will drug-treatment rates vary by geography, setting, and over time?<\/li>\n<li>What are the key drivers and constraints of the NHL \/ CLL therapy market, and how will the market evolve over the 2023-2033 forecast period? Which drug class will dominate the treatment of NHL \/ CLL?<\/li>\n<li>What will be the market impact of label expansions of BTK inhibitors, BiTEs, and CAR T-cell therapies into earlier lines of treatment across the different NHL \/ CLL subtypes?<\/li>\n<li>What are the most promising emerging therapies in the late-phase pipeline, and how will they shape the NHL \/ CLL therapy market over the forecast period?<\/li>\n<\/ul>\n<p><strong>Product description<\/strong><\/p>\n<p>Disease Landscape &#038; Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current and emerging therapies, and drug forecasts supported by detailed primary and secondary research.<\/p>\n<p><strong>Key features<\/strong><\/p>\n<p>Disease Landscape &#038; Forecast will be updated throughout the year to provide timely insights and analyses as material indication-specific news and events unfold.<\/p>\n<p>Disease Landscape &#038; Forecast features a Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.<\/p>\n","protected":false},"template":"","class_list":["post-389021","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-hodgkins-lymphoma","biopharma-therapy-areas-non-hodgkins-lymphoma-and-chronic-lymphocytic-leukemia","biopharma-date-985"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/389021","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/389021\/revisions"}],"predecessor-version":[{"id":575873,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/389021\/revisions\/575873"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=389021"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}